Management of Cancer Therapy Related Vulvovaginal Atrophy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-30

Study Completion Date

2021-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to:

1. evaluate the efficacy of PRP injection and PRP injection mixed with non-cross-linked hyaluronic acid compared to the control group receiving standard therapy with topical non-cross-linked hyaluronic acid gel in the treatment of cancer therapy-induced or worsened vulvovaginal atrophy.
2. To evaluate the impact of vulvovaginal atrophy treatment on the sexual satisfaction of both partners.

Patients will be divided randomly into 3 groups:

Group 1: 15 female patients will receive vaginal PRP injections. Group 2: 15 female patients will receive vaginal PRP injections combined with non-cross-linked hyaluronic acid.

Group 3: 15 female patients will receive topical non-cross-linked hyaluronic acid gel as a control group.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Autologous Platelet Concentrate Combined to Hyaluronic Acid Obtained With Cellular Matrix® BCT-HA Kit and Vulvovaginal Dryness

NCT02966925

Vulvar Atrophy

COMPLETED NA

Effect of PRP Injection in Releiving of Symptoms of Senile Vaginitis

NCT03898401

Senile Vaginitis

UNKNOWN PHASE1

POST-MARKETING CLINICAL STUDY to EVALUATE the EFFICACY and SAFETY of the VAGINAL FILLER MEDICAL DEVICE in CORRECTING THINNING of the GENITAL TISSUE of the LABIA MAJORA in WOMEN, RE-PROPORTIONING the FEMALE EXTERNAL GENITAL AREA and IMPROVING SEXUAL FUNCTION.

NCT06797167

Atrophy Vulva

COMPLETED NA

Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects

NCT02747641

Atrophy Vaginal Atrophy Genital Diseases, Female

COMPLETED NA

Subcision With PRP and Microneedling Versus Subcision With Saline and Micro-needling in Treatment of Posttraumatic Scars

NCT06135480

Post-Traumatic Scar

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. The first group will receive two treatment of sub-mucosal PRP injection at the outer 3 cm of the vagina with one month interval in between. (17)
2. The second group will receive two treatment of PRP injection mixed with non-cross linked hyaluronic acid at the outer 3 cm of the vagina with one month interval in between.

9\. 3-The third group will receive one applicator (5gm) three times per week of topical hyaluronic acid gel for vaginal application which will be prepared in the faculty of pharmacy for 2 months.

Clinical assessment Patients will be assessed for symptoms and signs of vulvovaginal atrophy (VVA) at baseline, one month, two months, and, three months after the end of treatment.

1. Vulvovaginal atrophy (VVA) symptoms (dryness, dyspareunia) will be assessed on a subjective 10-point scale.

Also, patient satisfaction with each type of treatment will be assessed with a questionnaire at the end of treatment and they will be asked if they wish to repeat the treatment to maintain effectiveness over time (yes or No).
2. For assessment of VVA signs on physical examination, vaginal health index including assessment of pH, overall elasticity, epithelial mucosa, fluid secretion type, and consistency and moisture will be used as an objective method of evaluation of therapy.
3. Assessment of sexual satisfaction of both male and female partners:

Sexual satisfaction was measured using the Arabic version of the Index of Sexual Satisfaction (ISS) and female sexual function index (FSFI) questionnaire.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Genitourinary Syndrome of Menopause

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PRP- treated Group A

15 female patients will receive 2 vaginal PRP injections one month apart.

Group Type ACTIVE_COMPARATOR

Platelet rich plasma

Intervention Type DEVICE

PRP can be considered a concentrate of autologous platelet-derived growth factors with known efficacy in tissue regeneration and wound healing.

PRP-HA treated Group B

15 female patients will receive 2 vaginal PRP-non-cross-linked HA injections spaced a month apart.

Group Type ACTIVE_COMPARATOR

Platelet rich plasma

Intervention Type DEVICE

PRP can be considered a concentrate of autologous platelet-derived growth factors with known efficacy in tissue regeneration and wound healing.

non cross-linked hyaluronic acid

Intervention Type DEVICE

HA filling is a known modality for rejuvenation

Control Group C

15 female patients will receive topical non-cross-linked hyaluronic acid gel applied every three days for 2 months as a control group

Group Type ACTIVE_COMPARATOR

topical HA gel

Intervention Type DEVICE

the standard treatment of vaginal atrophy and dryness

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Platelet rich plasma

PRP can be considered a concentrate of autologous platelet-derived growth factors with known efficacy in tissue regeneration and wound healing.

Intervention Type DEVICE

non cross-linked hyaluronic acid

HA filling is a known modality for rejuvenation

Intervention Type DEVICE

topical HA gel

the standard treatment of vaginal atrophy and dryness

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients have symptoms of VVA (vaginal dryness, burning, itching or dyspareunia)

* Patients with vaginal health index \< 15.
* All patients have already finished cancer therapy or are on anti-estrogen treatment.
* Married sexually active
* Patients who are not receiving any VVA treatment for at least 30 days before starting therapy.

Exclusion Criteria

* Active or recent history of vulvovaginal inflammation or infection

* History of vulvar or vaginal cancer.
* Suspicious lesion in the vulvovaginal area on the gynecological examination

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No